Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.Novo Nordisk (NVO 1.25%) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (LLY 0.99%) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Shares of both Novo Nordisk and Lilly have skyrocketed.However, the two market leaders could have significant competition on the way. Roche Holding (RHHBY 0.23%) underscored ...